MINNEAPOLIS, Feb. 26, 2014 /PRNewswire/ -- Uroplasty,
Inc. (NASDAQ: UPI), a medical device company that develops,
manufactures and markets innovative proprietary products for the
treatment of voiding dysfunctions, today announced that it will
participate in the 26th Annual ROTH Conference on Tuesday, March 11, 2014. Rob Kill, President and CEO, and Brett Reynolds, Chief Financial Officer, will
present at 8:30am PT and meet with
investors one on one at the conference at the Ritz Carlton in
Laguna Niguel, CA.
Attendance at the conference is by invitation only. A live
webcast of the presentation with accompanying slides will be
broadcast via the Internet. Those interested in joining the webcast
may access it through Uroplasty's website at www.uroplasty.com. An
archived replay of the presentation will be available for 90 days
following the event.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered
in Minnetonka, Minnesota, with
wholly-owned subsidiaries in The
Netherlands and the United
Kingdom, is a global medical device company that develops,
manufactures and markets innovative proprietary products for the
treatment of voiding dysfunctions. Our focus is the continued
commercialization of our Urgent® PC Neuromodulation System, the
only commercially available, FDA-cleared system that delivers
percutaneous tibial nerve stimulation (PTNS) for the office-based
treatment of overactive bladder (OAB). OAB is a chronic condition
that affects approximately 42 million U.S. adults. The
symptoms include urinary urgency, frequency and urge
incontinence. We also offer Macroplastique®, an injectable
urethral bulking agent for the treatment of adult female stress
urinary incontinence primarily due to intrinsic sphincter
deficiency. For more information on the company and its products,
please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information:
Uroplasty, Inc.
Brett Reynolds, SVP and
CFO
952.426.6152
EVC Group
Leigh Salvo (Investors)/Janine McCargo (Business Media)
415.568.9349/646.688.0245
SOURCE Uroplasty, Inc.